Publications by authors named "Yoshiro Fushimi"

Objective Immune checkpoint inhibitor-associated hypopituitarism (ICI-HP) is a rare immune-related adverse event (irAE) of ICIs. This study aimed to identify characteristic pituitary findings on magnetic resonance imaging (MRI) in ICI-HP. Methods This study is a single-center, retrospective, observational study.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to compare the effects of two diabetes medications, SGLT2 inhibitors (luseogliflozin) and DPP-4 inhibitors (teneligliptin), on β-cell function in type 2 diabetes patients over 26 weeks.
  • A total of 103 participants were included, with results showing improvements in the disposition index (a measure of insulin effectiveness) for both groups, but with more significant alleviation of β-cell dysfunction in the luseogliflozin group.
  • The findings suggest that while both drugs improve insulin secretion and sensitivity, luseogliflozin may be more effective at reducing β-cell dysfunction compared to teneligliptin.*
View Article and Find Full Text PDF
Article Synopsis
  • Tirzepatide, a dual agonist targeting specific receptors, is being studied for its effectiveness in treating obese type 2 diabetic patients, using a mouse model for evaluation.
  • In this study, obese db/db mice were treated with either tirzepatide or semaglutide, showing significant reductions in blood glucose and body weight, as well as improvements in β-cell function and liver health.
  • While both drugs demonstrated similar glucose-lowering effects, tirzepatide showed greater benefits on β-cell-related functions and liver parameters compared to semaglutide.
View Article and Find Full Text PDF

Objective This study aimed to examine the risk of diabetes mellitus induced by nilotinib, a second-generation tyrosine kinase inhibitor. Methods This retrospective study included 25 patients with chronic myeloid leukemia (CML) treated with nilotinib at our hospital. Four patients had diabetes mellitus at the start of nilotinib administration (prior DM group), and five patients were newly diagnosed with diabetes mellitus after the start of nilotinib administration (new DM group).

View Article and Find Full Text PDF

Aim: Recently, the development of the oral glucagon-like peptide-1 receptor agonist semaglutide has drawn a great deal of attention. This study aimed to compare the effectiveness of oral glucagon-like peptide-1 receptor agonist semaglutide and dipeptidyl peptidase-4 (DPP-4) inhibitors on glycaemic control and several metabolic parameters in patients with type 2 diabetes mellitus over a 6-month period.

Methods: Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.

View Article and Find Full Text PDF

Background: The impact of hand strength in consideration of sedentary behaviour on diabetes management in patients with type 2 diabetes mellitus (T2DM) is unclear. The purpose of this study was to examine the impact of hand strength on HbA1c, body mass index (BMI) and body composition by group according to the duration of sedentary behaviour in Japanese patients with T2DM.

Methods: In this retrospective, cross-sectional, single-centre study, hand strength standardised by bodyweight (GS) and sedentary time (ST), were obtained and analysed in a total of 270 Japanese T2DM outpatients in 2021.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from two groups of patients—those who were able to withdraw from insulin therapy and those who were not—finding that a higher CPI at 2 hours post-meal strongly correlated with successful withdrawal.
  • * The study concluded that the CPI after eating is an effective predictor of a patient's ability to stop insulin therapy, and the developed machine learning models showed a prediction accuracy between 78.3% and 82.6%.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how loss of muscle mass (measured by handgrip strength) and accumulation of visceral fat (measured by waist circumference) affect glycemic control in Japanese patients with type 2 diabetes.
  • A year-long observational study involved 233 patients with high HbA1c levels, analyzing how handgrip strength and waist circumference relate to improvements in glycemic control (HbA1c < 7.0%).
  • Results indicate that higher handgrip strength is linked to better glycemic control, while increased waist circumference negatively affects it; however, stronger handgrip strength can help lessen the negative impact of waist circumference.
View Article and Find Full Text PDF

Background: Imeglimin is a new anti-diabetic drug which promotes insulin secretion from pancreatic β-cells and reduces insulin resistance in insulin target tissues. However, there have been no reports examining the possible anti-atherosclerotic effects of imeglimin. In this study, we investigated the possible anti-atherosclerotic effects of imeglimin using atherosclerosis model ApoE KO mice treated with streptozotocin (STZ).

View Article and Find Full Text PDF

Aim: Dipeptidyl peptidase-4 (DPP-4) inhibitors suppress the inactivation of incretin hormones and lower blood glucose levels by inhibiting DPP-4 function. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels in an insulin-independent manner by inhibiting renal reabsorption of glucose. DPP-4 and SGLT2 inhibitors each have the potential to improve hepatic steatosis; however, their combined effects remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • * The study involved 327 patients and analyzed the associations between GS, WC, and BMI with glycemic control, adjusting for factors like age, sex, and medication use.
  • * Results indicated that GS was significantly linked to better glycemic control, whereas WC and BMI showed no significant variation across groups, suggesting that GS is a more reliable marker for managing diabetes risks in older adults.
View Article and Find Full Text PDF

Acute necrotizing esophagitis (ANE) is a rare and potentially life-threatening complication of diabetic ketoacidosis (DKA). While its association with DKA is established, specific clinical characteristics that predict ANE in DKA patients remain less understood. This study aimed to identify these characteristics by analyzing data from 30 DKA patients admitted from January 2018 to September 2022.

View Article and Find Full Text PDF
Article Synopsis
  • This study compares the effects of two weekly injections, dulaglutide and semaglutide, on managing blood sugar and weight in people with type 2 diabetes.
  • In "study 1," switching from dulaglutide to semaglutide resulted in significant reductions in HbA1c and body mass index after six months, especially for those initially struggling with blood sugar control.
  • "Study 2" found that patients who switched to semaglutide experienced better glycemic control and weight management compared to those who continued dulaglutide, suggesting that semaglutide may be the preferable option for obese patients with poor glycemic control.
View Article and Find Full Text PDF

Most primary hypothyroidism in adults is caused by chronic thyroiditis. Autoantibodies such as anti-thyroglobulin antibody (TgAb) and anti-thyroid peroxidase antibody (TPOAb) are involved in the pathogenesis of chronic thyroiditis. On the other hand, the clinical features of antibody-negative hypothyroidism are not clear.

View Article and Find Full Text PDF

Aim: To compare the clinical usefulness of once-weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide at the doses approved for use in Japanese patients with type 2 diabetes.

Methods: In total, 120 patients with glycated haemoglobin (HbA1c) ≥7% were randomly assigned to dulaglutide (n = 59) or semaglutide group (n = 61), and 107 participants (dulaglutide/semaglutide = 53/54) completed the 24-week trial. The primary endpoint was the difference of HbA1c level between the two groups at 24 weeks.

View Article and Find Full Text PDF

Primary aldosteronism (PA) is a well-known cause of secondary hypertension. We have long performed the simple standing test in patients with PA. On the other hand, there are few reports on the usefulness of the simple standing test in PA.

View Article and Find Full Text PDF
Article Synopsis
  • Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with thyroid dysfunction being the most common, but the impact on treatment response and survival remains unclear.
  • A study involving 466 patients treated with ICIs showed that 28.2% experienced thyroid dysfunction, and those with higher grades of dysfunction had significantly better 1-year survival rates and remission rates compared to those without thyroid dysfunction.
  • The findings highlight the need for regular monitoring of thyroid hormone levels in patients receiving ICIs, as thyroid dysfunction is linked to improved survival and treatment outcomes.
View Article and Find Full Text PDF

Background And Aims: Recently, pemafibrate, a selective PPARα modulator, has been developed as a treatment for hypertriglyceridemia and has attracted much attention. The aims of this study were to evaluate the efficacy and safety of pemafibrate in hypertriglyceridemia patients under clinical settings.

Methods And Results: We evaluated changes in lipid profiles and various parameters before and after 24-week pemafibrate administration in patients with hypertriglyceridemia who had not previously taken fibrate medications.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, programmed cell death protein 1 (PD-1) inhibitors, and programmed cell death protein 1 ligand 1 (PD-L1) inhibitors, are often used to treat a variety of malignancies. ICIs are known to cause endocrine-related immune-related adverse events (irAEs), but the incidence varies among reports and/or agents. This study evaluated the incidence of endocrine-related irAEs in patients who were treated with ICIs in Japan.

View Article and Find Full Text PDF

Objective The coronavirus disease 2019 (COVID-19) pandemic has led to a global restriction of public behavior due to lockdowns in various major cities. Lifestyle changes and reduced rates of outpatient lifestyle guidance/consulting may have had some impact on glycemic control in patients with type 2 diabetes. This study analyzed the impact of changes in the frequency of nutritional guidance/consulting (NGC) during the COVID-19 pandemic on outpatient care for type 2 diabetes.

View Article and Find Full Text PDF
Article Synopsis
  • Baba's diabetic neuropathy classification (BDC) is effective for assessing diabetic polyneuropathy (DPN) severity.
  • The study found significant correlations between BDC and complications such as diabetic retinopathy, nephropathy, and a history of heart or brain attacks.
  • The results indicate that BDC could help predict various diabetic complications, highlighting the need for more research on diabetes-related issues in patients with severe DPN.
View Article and Find Full Text PDF

Cushing's syndrome and subclinical Cushing's syndrome (SCS) are conditions of increased cortisol secretion from the adrenal glands. Cushing's syndrome includes adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome (Cushing's disease) and ACTH-independent Cushing's syndrome (AICS). The purpose of this study was to investigate the diagnostic potential of the cortisol / adrenocorticotropic hormone (ACTH) ratio (CAR) for diagnosis of Cushing's syndrome or SCS in adult subjects.

View Article and Find Full Text PDF

Decreased pancreatic volume, increased pancreatic fat mass, and serrated pancreatic margins are characteristic morphological changes of the pancreas in subjects with type 2 diabetes mellitus. This retrospective study aimed to clarify the clinical significance of pancreatic morphological changes in subjects with type 2 diabetes mellitus who underwent abdominal magnetic resonance imaging. The mean age and HbA1c value were 59.

View Article and Find Full Text PDF

Imeglimin is a new anti-diabetic drug commercialized in Japan (Twymeeg®) and has been drawing much attention in diabetes research area as well as in clinical practice. In this study, we evaluated the effect of imeglimin on pancreatic β-cells. First, single-dose administration of imeglimin enhanced insulin secretion from β-cells and decreased blood glucose levels in type 2 diabetic db/db mice.

View Article and Find Full Text PDF
Article Synopsis
  • * A study found that NTI was present in 80% of DKA patients, 70% of HHS patients, and 50% of diabetic ketosis (DK) patients, alongside significant changes in blood glucose and thyroid hormone levels upon treatment.
  • * The research suggests that NTI is common in acute metabolic failure due to hyperglycemia, and emphasizes that thyroid hormone replacement is usually unnecessary for those with NTI if they do
View Article and Find Full Text PDF